Literature DB >> 6372031

Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects.

W L George.   

Abstract

In the late 1970s it was found that Clostridium difficile causes a lethal, clindamycin-induced ileocecitis in the Syrian hamster; this animal model has been an invaluable aid to our understanding of antimicrobial agent-induced diarrhea in humans. C. difficile is involved in almost all cases of pseudomembranous colitis and in approximately one-fourth of cases of antimicrobial agent-associated diarrhea in humans in which a pseudomembrane is not detected. The presenting signs and symptoms of C. difficile-induced diarrhea are quite variable. Mild diarrhea may be the only finding in the least severe form of disease, whereas patients with severe disease may have high fever, leukocytosis, severe abdominal cramping, marked abdominal tenderness, and profuse diarrhea. Occasionally, symptoms may be so marked as to simulate an acute intraabdominal catastrophe. Diagnosis of C. difficile-induced disease usually is made by detecting C. difficile cytotoxin in the feces of a patient. Assay for cytotoxin in feces of infants is not reliable for diagnosis, however, because of the high incidence of an asymptomatic carrier state in this group. Appropriate therapy includes discontinuation of the offending antimicrobial agent and administration of oral vancomycin when specific antibacterial treatment is indicated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6372031     DOI: 10.1093/clinids/6.supplement_1.s208

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  20 in total

1.  Molecular and genomic analysis of genes encoding surface-anchored proteins from Clostridium difficile.

Authors:  T Karjalainen; A J Waligora-Dupriet; M Cerquetti; P Spigaglia; A Maggioni; P Mauri; P Mastrantonio
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization.

Authors:  A Tasteyre; M C Barc; A Collignon; H Boureau; T Karjalainen
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  Treatment of acute uncomplicated urinary tract infection with ceftibuten.

Authors:  G E Stein; S Christensen; N Mummaw
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

Review 4.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

5.  Identification of a novel virulence factor in Clostridium difficile that modulates toxin sensitivity of cultured epithelial cells.

Authors:  Masashi Miura; Haru Kato; Osamu Matsushita
Journal:  Infect Immun       Date:  2011-07-11       Impact factor: 3.441

6.  Isolation of Clostridium difficile and detection of cytotoxin in the feces of diarrheic foals in the absence of antimicrobial treatment.

Authors:  R L Jones; W S Adney; R K Shideler
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

7.  Characterization of a cell surface protein of Clostridium difficile with adhesive properties.

Authors:  A J Waligora; C Hennequin; P Mullany; P Bourlioux; A Collignon; T Karjalainen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues.

Authors:  Emanuela Calabi; Franco Calabi; Alan D Phillips; Neil F Fairweather
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea.

Authors:  C Wenisch; E Etzersdorfer; S Breyer; W Graninger
Journal:  Clin Investig       Date:  1994-11

10.  Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement.

Authors:  J C Siffert; O Baldacini; J G Kuhry; D Wachsmann; S Benabdelmoumene; A Faradji; H Monteil; P Poindron
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.